AN ULCERATIVE COLITIS DECISION SUPPORT TOOL PREDICTS DRUG SPECIFIC ENDOSCOPIC REMISSION AND IMPROVES PROVIDER MASTERY IN TREATMENT SELECTION

被引：0
|
作者：
Dulai, Parambir S.
Wong, Emily C.
Johnson, Beth
Cox, Kenny
Theriault, Nicolette
Stefan, Margie
Eldasher, Lobna M.
Narula, Neeraj
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1712
引用
收藏
页码：S647 / S647
页数：1
相关论文
共 8 条
  • [1] Application of a clinical decision support tool for predicting biochemical remission with vedolizumab therapy in patients with ulcerative colitis
    Kim, Kyuwon
    Oh, Kyunghwan
    Hong, Hee Seung
    Lee, Jae Yong
    Hong, Seung Wook
    Park, Jin Hwa
    Hwang, Sung Wook
    Park, Sang Hyoung
    Yang, Dong-Hoon
    Byeon, Jeong-Sik
    Myung, Seung-Jae
    Yang, Suk-Kyun
    Ye, Byong Duk
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 273 - 273
  • [2] Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
    Dulai, Parambir S.
    Wong, Emily C. L.
    Reinisch, Walter
    Colombel, Jean-Frederic
    Marshall, John K.
    Narula, Neeraj
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (10) : 1555 - 1564
  • [3] Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis
    de Voogd, Floris A.
    Bots, Steven J.
    van Wassenaer, Elsa A.
    de Jong, Maria
    Pruijt, Maarten J.
    D'Haens, Geert R.
    Gecse, Krisztina B.
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (11) : 1992 - 2003
  • [4] Early intestinal ultrasound predicts endoscopic response to anti-inflammatory treatment and shows drug-specific response to biologicals and tofacitinib in Ulcerative Colitis
    de Voogd, F.
    Bots, S.
    Van Wassenaer, E.
    De Jong, M.
    Pruijt, M.
    Lowenberg, M.
    D'Haens, G.
    Gecse, K.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I060 - I062
  • [5] EARLY INTESTINAL ULTRASOUND PREDICTS ENDOSCOPIC RESPONSE ON ANTI-INFLAMMATORY TREATMENT AND SHOWS DRUG-SPECIFIC RESPONSE TO BIOLOGICALS AND TOFACITINIB IN ULCERATIVE COLITIS
    De Voogd, Floris
    Bots, Steven
    Van Wassenaer, Elsa A.
    de Jong, Maria
    Pruijt, Maarten
    Lowenberg, Mark
    D'Haens, Geert
    Gecse, Krisztina B.
    GASTROENTEROLOGY, 2022, 162 (07) : S612 - S613
  • [6] Clinical decision support tool for vedolizumab can predict treatment persistence in Crohn's disease but not in ulcerative colitis
    Ocepek, A.
    Molinari, N.
    Macek, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1847 - I1847
  • [7] Normalization or reduction of at least 50% in faecal calprotectin levels after 3 months of treatment predicts clinical and endoscopic remission at 1 year in patients with ulcerative colitis: results of the prospective MIROIR study
    Buisson, A.
    Coban, D.
    Bazoge, M.
    Dodel, M.
    Pereira, B.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i863 - i863
  • [8] Pilot Assessment of the BMET Decision Support Platform: A Tool to Improve Provider Survival Estimates and Selection of Prognosis-Appropriate Treatment for Patients with Symptomatic Bone Metastases
    Alcorn, S. R.
    Fiksel, J.
    Hu, C.
    Wright, J. L.
    Kleinberg, L. R.
    Levin, A. S.
    Smith, T.
    Cheng, Z.
    Elledge, C. R.
    Kim, K.
    Rao, A. D.
    Sloan, L.
    Page, B. R.
    Stinson, S. F.
    Voong, R.
    McNutt, T. R.
    Bowers, M. R.
    DeWeese, T. L.
    Zeger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S47 - S47
1